Current Perspectives in Atrophic Gastritis.
Atrophic gastritis
Chromoendoscopy
Gastric cancer
Gastric microbiota
Helicobacter pylori
Intestinal metaplasia
Journal
Current gastroenterology reports
ISSN: 1534-312X
Titre abrégé: Curr Gastroenterol Rep
Pays: United States
ID NLM: 100888896
Informations de publication
Date de publication:
15 Jun 2020
15 Jun 2020
Historique:
entrez:
17
6
2020
pubmed:
17
6
2020
medline:
24
4
2021
Statut:
epublish
Résumé
Atrophic gastritis is a complex syndrome with gastric atrophy as a common trait. Helicobacter pylori infection and autoimmunity are the two main contexts in which it develops. It is slightly symptomatic, affects various aspects of general health, and remains a predisposing factor for gastric cancer. This review will update current knowledge and progress on atrophic gastritis. Atrophic gastritis affects mostly adults with persistent dyspepsia, deficient anemia, autoimmunity disease, long-term proton pump inhibitor use, and a family history of gastric cancer. Gastric biopsies, expressed as Sydney system grade and OLGA/OLGIM classifications, represent the gold standard for diagnosis and cancer risk stage, respectively. Recently, electronic chromoendoscopy has allowed "targeted biopsies" of intestinal metaplasia. The associated hypochlorhydria affects the gastric microbiota composition suggesting that non-Helicobacter pylori microbiota may participate in the development of gastric cancer. Physicians should be aware of multifaceted clinical presentation of atrophic gastritis. It should be endoscopically monitored by targeted gastric biopsies. Autoimmune and Helicobacter pylori-induced atrophic gastritis are associated with different gastric microbial profiles playing different roles in gastric tumorigenesis.
Identifiants
pubmed: 32542467
doi: 10.1007/s11894-020-00775-1
pii: 10.1007/s11894-020-00775-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM